cefuroxime has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Durojaiye, AB | 1 |
| Clarke, JD | 1 |
| Stamatiades, GA | 1 |
| Wang, C | 1 |
1 review available for cefuroxime and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Repurposing cefuroxime for treatment of COVID-19: a scoping review of
Topics: Cefuroxime; Computer Simulation; COVID-19; Drug Repositioning; Humans; Molecular Docking Simulation; | 2021 |